遺伝性ATTRアミロイドーシスの病態に基づいた疾患修飾療法の開発

DOI
  • 関島 良樹
    信州大学医学部脳神経内科，リウマチ・膠原病内科

書誌事項

タイトル別名
  • Development of disease modifying therapies to ameliorate hereditary ATTR amyloidosis

この論文をさがす

説明

<p>Transthyretin (TTR) is a representative amyloidogenic protein in humans. TTR protein destabilised by TTR gene mutation is prone to dissociate from its native tetramer to monomer, then misfold and aggregate into amyloid fibrils, which results in autosomal dominant hereditary ATTR amyloidosis. Patients with hereditary ATTR amyloidosis show progressive sensorimotor neuropathy, autonomic dysfunction, cardiomyopathy, cerebral amyloid angiopathy, and ocular amyloidosis. In the natural course, patients die 10 to 15 years after the onset due to malnutrition, infection, or cardiac failure. Liver transplantation used to be the only disease modifying therapy for hereditary ATTR amyloidosis, which allows suppression of the main source of variant TTR. However, large numbers of patients are not suitable transplant candidates because of their age and/or advanced disease status. Recently, clinical effects of TTR tetramer stabilisers, tafamidis and diflunisal, were demonstrated in randomized controlled trials, and tafamidis has been approved for the treatment of hereditary ATTR amyloidosis in more the 30 countries. In addition, gene therapies with small interfering RNAs (siRNAs) and antisense oligonucleotides are promising strategies to ameliorate hereditary ATTR amyloidosis. Patisiran is an investigational RNA interference (RNAi) therapeutic agent that binds to a conserved sequence in the TTR messenger RNA in the liver. The results of phase III clinical trial of patisiran was disclosed at the end of 2017, which showed its excellent efficacy and tolerability in hereditary ATTR amyloidosis patients.</p>

収録刊行物

  • 神経治療学

    神経治療学 35 (3), 278-282, 2018

    日本神経治療学会

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ